ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Other Income / Expenses history
Currency unavailable · from the income statement
No Other Income / Expenses data reported for this period type.
Other Income / Expenses vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.2M USD | +6.7% | +60.9% | 44.3% | |
| LTM Mar 2026 | $13.29M USD | -1.0% | +91.1% | 18.5% | |
| LTM Mar 2026 | $10.54M USD | -22.0% | — | 23.2% | |
| LTM Mar 2026 | $8.24M USD | +88.4% | — | 204.2% | |
| LTM Mar 2026 | $5.05M USD | +38.6% | — | — | |
| LTM Mar 2026 | $1.43M USD | — | -50.1% | 155.2% | |
| LTM Mar 2026 | €840.44K EUR | -70.3% | +16.3% | 6.3% | |
| FY2025 | -$12K USD | — | — | 0.1% | |
| LTM Mar 2026 | -$15.34M USD | -85.0% | — | 19.2% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -1.0% | +38.6% | 21.2% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.